GlassScriptPhysician profile
Timothy G Mcgarry
NPI 1245225465
$18,538.59
in general payments reported to CMS, 2019-2025
23 companies · $6,201 in 2025
The $6,201 reported for 2025 was more than what 84% of Orthopaedic Surgery providers received nationally (typical 2025 total: $569).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,614 · 2020: $2,355 · 2021: $2,127 · 2022: $195 · 2023: $1,626 · 2024: $4,421 · 2025: $6,201.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $8,925 · Food and Beverage: $3,018 · Consulting Fee: $305.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $8,925.11 |
| Food and Beverage | $3,017.86 |
| Consulting Fee | $305.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zimmer Biomet Holdings, INC. | $7,366.63 | 2020-2025 | Persona, Oxford, Tapestry |
| Stryker Corporation | $3,081.48 | 2019-2025 | Mako, Tritanium |
| Medacta USA, INC. | $2,042.99 | 2019-2020 | |
| Fx Shoulder Solutions, INC | $1,727.21 | 2022-2024 | |
| Encore Medical, LP | $1,200.00 | 2021 | |
| Arthrex, INC. | $1,069.90 | 2025 | |
| Smoky Mountain Surgical LLC | $794.66 | 2025 | |
| Hikma Pharmaceuticals USA | $305.33 | 2024 | Combogesic IV |
| Pacira Therapeutics, INC. | $224.35 | 2020-2021 | |
| Ferring Pharmaceuticals INC. | $162.44 | 2019-2024 | Euflexxa |
| Horizon Therapeutics Plc | $155.03 | 2020-2022 | |
| Heron Therapeutics, INC. | $88.83 | 2025 | Zynrelef |
| Allergan, INC. | $56.96 | 2019 | |
| Avanos Medical | $41.50 | 2019-2021 | |
| Bioventus LLC | $39.80 | 2019-2020 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Smith+Nephew, INC. | $34.55 | 2019-2024 | Renasys Touch, Pico |
| Kci USA, INC. | $30.13 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $26.50 | 2022 | |
| Organogenesis INC. | $22.77 | 2022 | |
| Convatec INC. | $20.63 | 2019 | |
| Conformis, INC. | $17.55 | 2019 | |
| Pacira Pharmaceuticals Incorporated | $14.84 | 2023 | Exparel, Iovera, Zilretta |
| Depuy Synthes Sales INC. | $14.51 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Mcgarry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.